Topical Betaxolol for the Prevention of Retinopathy of Prematurity

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Smith-Kettlewell Eye Research Institute
• Collaborators: Ohio State University; The University of Texas Health Science Center, Houston; University of Minnesota; University of Minnesota - Clinical and Translational Science Institute; University of Oklahoma
• Treatments: Betaxolol

Criteria

Inclusion Criteria:

• <1251 grms birth weight

Exclusion Criteria:

• ocular defect